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Abstract
Background: The discovery and development of new anti-malarials are at a crossroads. Fixed dose artemisinin
combination therapy is now being used to treat a hundred million children each year, with a cost as low as 30
cents per child, with cure rates of over 95%. However, as with all anti-infective strategies, this triumph brings with
it the seeds of its own downfall, the emergence of resistance. It takes ten years to develop a new medicine. New
classes of medicines to combat malaria, as a result of infection by Plasmodium falciparum and Plasmodium vivax
are urgently needed.
Results: Natural product scaffolds have been the basis of the majority of current anti-malarial medicines. Molecules
such as quinine, lapachol and artemisinin were originally isolated from herbal medicinal products. After
improvement with medicinal chemistry and formulation technologies, and combination with other active
ingredients, they now make up the current armamentarium of medicines. In recent years advances in screening
technologies have allowed testing of millions of compounds from pharmaceutical diversity for anti-malarial activity
in cellular assays. These initiatives have resulted in thousands of new sub-micromolar active compounds – starting
points for new drug discovery programmes. Against this backdrop, the paucity of potent natural products
identified has been disappointing. Now is a good time to reflect on the current approach to screening herbal
medicinal products and suggest revisions. Nearly sixty years ago, the Chinese doctor Chen Guofu, suggested
natural products should be approached by dao-xing-ni-shi or ‘acting in the reversed order’, starting with
observational clinical studies. Natural products based on herbal remedies are in use in the community, and have
the potential unique advantage that clinical observational data exist, or can be generated. The first step should be
the confirmation and definition of the clinical activity of herbal medicinal products already used by the
community. This first step forms a solid basis of observations, before moving to in vivo pharmacological
characterization and ultimately identifying the active ingredient. A large part of the population uses herbal
medicinal products despite limited numbers of well-controlled clinical studies. Increased awareness by the
regulators and public health bodies of the need for safety information on herbal medicinal products also lends
support to obtaining more clinical data on such products.
Conclusions: The relative paucity of new herbal medicinal product scaffolds active against malaria results
discovered in recent years suggest it is time to re-evaluate the ‘smash and grab’ approach of randomly testing
purified natural products and replace it with a patient-data led approach. This will require a change of perspective
form many in the field. It will require an investment in standardisation in several areas, including: the
ethnopharmacology and design and reporting of clinical observation studies, systems for characterizing anti-
malarial activity of patient plasma samples ex vivo followed by chemical and pharmacological characterisation of
extracts from promising sources. Such work falls outside of the core mandate of the product development
partnerships, such as MMV, and so will require additional support. This call is timely, given the strong interest from
researchers in disease endemic countries to support the research arm of a malaria eradication agenda. Para-
national institutions such as the African Network for Drugs and Diagnostics Innovation (ANDi) will play a major role
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any medium, provided the original work is properly cited.in facilitating the development of their natural products patrimony and possibly clinical best practice to bring
forward new therapeutics. As in the past, with quinine, lapinone and artemisinin, once the activity of herbal
medicinal products in humans is characterised, it can be used to identify new molecular scaffolds which will form
the basis of the next generation of anti-malarial therapies.
The need for new classes of medicines
Malaria remains one of the most significant health
issues that we face today, with 250 million cases, and
over 800,000 deaths annually. This impact is multiplied
by the fact that 85% of the cases are in children under
five years old, and the prevalence is high amongst
expectant mothers. The current gold standard medicine
is the fixed dose artemisinin combination therapy: con-
sisting of chemical derivatives of the Chinese natural
product artemisinin, and a longer acting partner (an ary-
lamino alcohol or 4-amino quinoline), which ultimately
traces its ancestry back to the natural product quinine.
These medicines are extraordinary effective, curing
more 98% of patients (measured 28 days after treatment,
to make exclude patients who recrudesce). They are also
relatively safe, often with no serious adverse events seen
in phase III trials of several thousand patients. They are
also relatively cheap: the cost of a cure for the smallest
of children can be as low as $0.33 when purchased by
the public sector in disease endemic countries. However,
in the long term there will always be a need for new
therapies – no matter how carefully the current medi-
cines are used then there is the constant threat of resis-
tance. The first signs of resistance to artemisinins are
emerging, with patients taking longer to clear their fever
and parasite in some parts of Cambodia [1]. This is an
early warning sign that new classes of anti-malarials are
needed, and are an urgent priority. It takes at least ten
years to move a molecule from late in the discovery
phase to completion of clinical trials, and there is a rela-
tive dearth of compounds with new mechanisms of
action in clinical development at this time. Natural pro-
ducts and their derivatives have been a powerful part of
the fight against malaria in the past – however, success
requires that the lessons of the past are not disregarded.
A revolution in screening: micromolar activity on
its own is not enough
In the search for new medicines to combat malaria there
have been two major technological steps forward over
the last ten years. First, the parasite genomes have been
sequenced, allowing, a systematic analysis of all the
essential and ‘druggable’ genes. This has allowed assays
to be set up for screening with the hope of finding new
starting points for chemical programmes [2]. Second,
advances in image processing and automation technol-
ogy allow that assays for live parasites inside human
host cells to be run in 384 or 1,536 well formats [3,4],
making screening a hundred times faster and a hundred
times cheaper than ten years ago. These technological
advances have meant that the malaria community can
now screen millions of compounds from the pharma-
ceutical industry, both in-house and also as collabora-
tions with academic centres [5]. The results for malaria
have been surprisingly good, with hit rates (compounds
with confirmed IC50 values of less than 1 μM) of 0.5%.
The frequency at which these cell-based screening hits
occur is an important factor in analysing the best way
to discover new medicines. For example, the hit rates in
assays using live parasites in erythrocytes are higher
those often found screening many classes of molecular
targets. The live parasite approach is also one step
ahead of target based approaches, in that the hits are
already known to kill parasites, so have addressed cellu-
lar permeability question. They will also have been
counter-screened against a human cell line, to show lack
of toxicity [6]. The next important question for new hits
is to know whether they will be active against existing
drug-resistant strains of malaria, and this can be inte-
grated into the cell biology at the outset. Where such
clinical isolates do not exist, early information on the
way resistance could occur to these new compounds
can be rapidly obtained by in vitro generation of resis-
tance, and sequencing. Compounds identified in this
way can be successfully optimized without knowing the
precise molecular target. Target identification can be
performed in parallel to the lead optimisation process.
Indeed, the molecules may have multiple molecular tar-
gets, and this would be an advantage in combating the
emergence of resistance [7]. Cell-based screening has
been a success. But the most important message is that
now there are 25,000 distinct pure compounds with
potencies against the parasite of less than one micromo-
lar in vitro covering over a thousand different scaffolds,
many of these in the public domain. These have been
rapidly advanced to clinical candidates.
This resets the way that the relative success of herbal
medicinal products approaches to anti-malarial drug dis-
covery are measured. They have not fared nearly so well
recently: only three hundred new anti-malarial com-
pounds have been isolated from plants used in tradi-
tional medicine over the period 2005 to 2008 [8].
However, the reality is even more problematic, since
these authors used a cut-off of 11 micromolar in their
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cal screening is applied, only 20 new structures pass, a
much lower yield than from screening pharmaceutical
diversity. Unfortunately, much of the subsequent natural
products evaluation work in the literature is still focused
on these low potency molecules; arguably an opportu-
nity cost. Setting a more stringent cut-off makes sense
from a number of other perspectives. First, clinical rea-
lity: few molecules are present in plasma with free con-
centrations above 1 μM for significant lengths of time in
human. Second, as the potency cut-off is weakened, the
chances of random interactions with the cell increase,
opening up the possibility of toxicity [9]. The natural
products will tend to have a low ligand efficiency, low
p o t e n c ya n dl a r g en u m b e ro fh e a v ya t o m s[ 1 0 ] ,w h i c h
makes them less attractive as starting points, (unless it
is already known they are active in human). There are
several purified natural products, which were identified
as active molecules in the hits obtained by screening
diversity from the pharmaceutical diversity collections.
But even these have not yielded many useful new start-
ing points [11], often only finding antibiotics with
known anti-malarial activities, such as the macrolide
family. In brief, the new-found ability to screen pharma-
ceutical diversity against parasites in malaria-infected
cells suggests a reassessment of the standards for suc-
cess in natural products based screening. Either a nat-
ural product hit must be dramatically more potent;
(many of the oncology based natural products hits are
single digit nanomolar), or it must have some other
clearly definable advantage. One such major advantage
would be knowing clearly from the start that the pre-
paration worked in humans. That it has a defined clini-
cal activity which could be reproducibly observed in
malaria patients, and without obvious acute toxicology.
This is most often overlooked.
The historical importance of natural products
The history of anti-malarial chemotherapy is intimately
linked with the history of herbal medicinal products.
Quinine, the original natural product used in anti-
malarial chemotherapy was identified from cinchona
tree bark, and purified in 1820. The attempt to synthe-
size quinine led to the development of methylene blue
and the dye industry. From this came the classical 4-
aminoquinolines and amino-alcohols, such as chloro-
quine, amodiaquine and mefloquine, which have been
the mainstay of malarial treatment over the last century.
The natural product naphthoquinone lapichol also was
identified as the active ingredient in tree bark used to
treat malaria. This discovery helped direct the selection
of lapinone, which in turn provided the foundation for
the discovery of atovaquone, a component of Malar-
one
®, still a mainstay of malaria prophylaxis for
travellers [12]. Artemisinin was first isolated from the
leaves of the sweet wormwood – Artemisia annua in
1971. The highly unusual endoperoxide group has
formed the basis for a range of fully synthetic, longer
acting molecules which are now in clinical development
[13], and which may be the basis of the next generation
of therapies, active against artemisinin-resistant malaria.
The pattern is consistent: initial identification of natural
product scaffolds, followed by their modification for
clinical use by a combination of medicinal chemistry,
formulation development and combination therapy.
The continual emergence or threat of emergence of
drug resistance means that there will always be a need
for new classes of molecules to combat malaria. The
relative lack of success in finding new potent natural
product scaffolds, could be taken to suggest natural pro-
ducts will be relatively less prominent in the future.
However, before jumping to a premature conclusion it
is important to focus on the other potential advantages
of natural products.
(a) Natural products represent a source of potential
new pharmacophores, the warheads that are needed for
killing the parasite. Here it is important to distinguish
between new pharmacophores and those which are
already known to be cytotoxic. The latter are often seen
as ‘frequent hitters’ in cellular screens (aptly named
PAINs or pan-assay interfering compounds [14]) includ-
ing tannins and polyphenols. It is also important to
underline that many of the exotic chemical structures
are chemically reactive Michael acceptors, which often
are toxic due to irreversible covalent modification of
host proteins and organs. What success really looks like
is a novel molecule, which would give a new chemical
insight, represent a novel mechanism of action, such as
the artemisinin endoperoxide. It has to be underlined
that many new scaffolds found in natural products will
raise some concerns with medicinal chemists: quinine
and artemisinin would be good examples here. These
concerns are only going to be overcome by data, evi-
dence of a wide cellular selectivity window, and thera-
peutic window in preclinical animal models.
(b) Herbal medicinal products are often perceived by
the patient community as being safe, and many have
been used by communities in disease endemic countries
for generations. This safety question is not restricted to
neglected diseases. In the US over 19% of the adult
population use a herbal medicinal product[15], and the
regulatory authorities have been obliged to develop a
position on such products. Long-term medicinal or food
use is currently accepted by some regulatory authorities
as evidence of an adequate acute safety profile [16].
However, there are few studies of chronic safety data for
most herbal medicinal products. This lack of well-docu-
mented safety data is concerning in the context of
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l a t i o n ss u c ha ss m a l li n f a n t sa n de x p e c t a n tm o t h e r s .
Even though malaria is an acute disease, it is important
to demonstrate safety after repeat dosing. In many parts
of Africa, a child can have more than ten episodes of
malaria per year. Significant caution must therefore be
taken when assessing the chronic safety liabilities, espe-
cially questions around genotoxicty. This is illustrated
by examples such as the herbal medicinal product aris-
tolochic acid, incorrectly prescribed for weight loss (not
an indication recommended by the traditional healers).
Initial safety concerns were raised by acute renal failure
in some patients [17]. The long-term perspective is
equally distressing, as bladder cancer being observed in
patients fifteen years after cessation of treatment [18].
This case serves as a reminder that plant secondary
metabolites are generally produced as part of the host
d e f e n c em e c h a n i s m ,a n da r el i k e l yt oh a v es o m ed e t e r -
rent effect. The objective in anti-malarial therapy is to
identify compounds which are selectively toxic against
the parasite rather than the host.
(c) There is a strong desire on the part of the malaria
endemic countries to be more active in using their eth-
nopharmacological heritage to identify new medicines to
combat malaria. For example, the recently formed Afri-
can Network for Drugs and Diagnostics Innovation
(ANDi) has highlighted the role African countries can
play in discovering new medicinal products [19]. In
their 2009 meeting, half of the projects presented
described the activities of un-purified natural products.
Such projects fall outside the core activities of product
development partnerships such as Medicines for Malaria
Venture. However, support for such research activities
by governments of disease endemic countries via organi-
zations such as ANDi would be consistent with the
pledges of the signatories of the 2000 Abuja declaration
to increase support for research (including operational
research) to develop new tools and improve existing
ones. The development of herbal medicinal products are
one of the areas where researchers from disease ende-
mic countries can have a large impact [20]
(d) Herbal medicinal products are used by the com-
munity. This means that there is anecdotal evidence of
their efficacy by the community. This is actually the key
success factor. Its weight is strengthened if use of the
same active ingredient has been documented to be used
by several communities. If the definition of what is safe
and active in human can be standardized, and the clini-
cal activity defined, and plasma samples from patients
can be shown to have ex-vivo activity, decisions can be
made at an early stage which products to work on and
purify further. This would allow a substantial focusing
of natural product related drug discovery.
Back to the roots – retracing how to find
interesting natural products
The key question then becomes whether success with
natural products can be improved by starting with
extracts which have associated ethno-pharmacology
data; those suggested to be active by the local traditional
h e a l e r s .T h ef i r s th u r d l et oo v e r c o m ei st oc o n f i r mt h a t
the extract has some activity in patients (Figure 1).
Many investigations fail at this point, taking for granted
that their understanding of the clinical activity in some
way relates to the understanding of the traditional hea-
ler. Before embarking on a costly and extensive charac-
terization of a root or bark extract, it would be better to
have confirmation that the extract is active in controlled
studies in addition to the anecdotal reports.
Observation of pharmacological activity and safety in
patients with malaria must be carried out within strict
ethical guidelines [21]. Studies should be performed
where the plant extract is the preferred treatment [22],
there is a long history of use, well documented side
effect profiles, and all subjects should give informed
consent. Understanding safety is paramount, and so
questions about side effects, contraindications, use in
pregnancy and treatment duration need are essential
[23]. Extracts which have been claimed as active by
more than one community are more likely to yield a
coherent molecular hypothesis. There needs to be a well
documented method for pharmacognosy; the identifica-
tion of the plants and the preparation of the extract,
supported with an analytical profile of the extract. Close
follow up and rescue therapy for treatment failures are
essential. In order to separate anti-malarial activity from
simple anti-pyretic activity, WHO diagnostic criteria for
malaria infection of >2,000 parasites/ml in high trans-
mission areas, (>1,000 parasites/ml in low transmission
areas), temperature above 37.5
oC and no concomitant
infection should ideally be applied. In Africa, the semi-
immune status of patients greater than five years old,
will have a significant impact on cure rates at day 14,
rendering rates of < 50% of questionable significance
(see reference [24], Table 4). Therefore, it is important
to know the age distribution of the patients (< 1 year
old, between 1 and 5 years and over 5), the dose
response and to know what proportion of patients
achieved adequate clinical and parasitological response
(ACPR) up to day 28. Although current WHO guide-
lines require treatments to have an APCR of >95% at
day 28 [25] for new combination treatments, this is too
rigorous for analysing the initial clinical data of natural
product extracts. The expectations for the initial activity
need to be more realistic than this, and based on histor-
ical successes with earlier generations of natural pro-
ducts. Certainly neither Cinchona nor Artemisia extracts
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chemical modification, formulation and combination of
these natural products produces improved medicines
with >95% cure rates after three days of treatment, but
this has taken many years of development work. The
same process of optimization will be required for any
new therapeutically active natural products. Finally, the
identification of the active metabolite is very important,
and it would be good to retain plasma and urine sam-
ples for metabolite analysis. Table 1 shows details of
some of the natural products, which have been con-
firmed in observational clinical studies. As can be seen,
often several of the key clinical parameters have been
obtained, but rarely are all the key parameters for an
observational study available. There is a clear need to
define guideline protocols for such studies, as well as a
central database of ongoing studies. The molecular
details of the main active ingredients are also given.
H e r et h e r ei sl e s sc l a r i t y ,s ince there are limited data
about the activity of purified compounds in vivo,a n d
there is plenty of scope in many of these molecules for
interesting metabolic transformations carried out by
either the gastrointestinal tract or hepatic metabolism in
the human patient. This point is critical: the active
ingredient may not be present in the initial herbal med-
icinal product, and its production may be restricted to
processes which only occur in the human absorption or
human metabolism. A standard analytical process for
plasma, urine and plant samples would also be a great
asset here along with standardized testing of the purified
molecules. In addition a standardized process for testing
plasma samples from patients in these studies against
parasites ex vivo would be highly beneficial.
Dao-xing-ni-shi
The approach of starting with the activity in humans
was suggested in 1952 by Chen Guofu when working on
the Chinese herbal medicinal product Ch’ang shan and
was labelled dao-xing-ni-shi or ‘acting in the reversed
order’ [26]. At the time there were major objections by
Clinical
Observations. 
Define activity of 
extracts on 
patients
(parasitaemia, 
temperature,
duration of 
response, 
age/immune 
status)
Obtain plasma 
samples for LC-
MSMS analysis, 
Confirm activity 
of plasma
samples against 
the parasite ex 
vivo
In vivo 
pharmacology 
Define activity of 
extracts in 
murine models: 
confirm if activity 
is only against 
P. falciparum.
Define if 
metabolism is 
needed/different 
in mouse.Obtain 
plasma samples 
for LC-MS/MS 
analysis 
Cellular
pharmacology 
Test extracts 
against P.
falciparum blood 
stages (and liver 
stages) in culture
Confirm activity 
seen at 
concentrations 
consistent with 
plasma levels in 
man and mouse 
Fractionation 
Separate into 
active fractions. 
Confirm that total 
activity is not lost 
by fractionation. 
If activity lost: 
confirm whether 
this is due to 
unstable 
molecules or 
activity residing 
in more than one 
molecule
(synergy) 
Figure 1 A high level scheme for identifying natural products based on ethnopharmacology. A high level scheme for identifying natural
products based on ethnopharmacology. Screening strategies should be led by the initial confirmation that extracts have pharmacological
activity at some level in the human disease and a clear absence of acute adverse events. Confirmation of such safety and efficacy from more
than one study and community would be an advantage. Such a scheme would focus natural products research, prioritising those with
confirmed activity in man. This process is an updated version of Yu Yunxiu’s 1952 doa-xing-ni-shi (acting in the reversed order) or 54321 [25].
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using patients as guinea pigs, and there were additional
concerns regarding using un-purified materials. In the
intervening sixty years, several factors have ameliorated
these concerns. First, acceptance by authorities such as
the European Medicines Agency, the US-FDA and the
WHO, that since patients and communities use herbal
medicinal products, there is a public health responsibility
to understand them better and produce guidelines
around their preparation, usage and safety. Some disease
endemic country regulatory authorities have already
approved herbal medicinal products, and so carry an
addition responsibility to ensure ongoing data collection
on clinical safety and efficacy. Second, the assays for test-
ing the anti-malarial activities of samples are now extre-
mely robust, and can be run with relatively low volumes.
This means that any plasma or urine sample taken from
a patient can be initially tested to see if it has anti-malar-
ial activity ex-vivo. Third, analytical methodologies and
technologies are available which allow detailed analysis of
the plant material by liquid chromatography and mass
spectrometry, and a comparison with plasma and urine
samples from patients. Combining these approaches with
our growing understanding of xenobiotic metabolomics,
offers the possibility to identify the active ingredients in
human. Recent advances in analysis coupled with statisti-
cal analysis and mathematical modelling provide a base-
line for such studies [27,28]. It may well be that the
original herbal medicinal product has to be metabolized
in the gastrointestinal tract or liver to produce the active
ingredient. In this case, the original extract would not
have a high degree of activity in cell-based assays. It may
also have sub-optimal activity in murine in vivo assays, if
either there are significant differences in either the mur-
ine metabolism or potency against rodent parasite. There
are many examples in malaria therapy of metabolism
being required for activity. 8-aminoquinolines are active
against the blood and hepatic stages of Plasmodium but
require hepatic metabolism [29]. Extracts from Nauclea
pobeguinii are active in both rodent models and patients,
d e s p i t en o n eo ft h ea l k a l o i d ss h o w i n gin vitro activity,
suggesting activation of strictosamide, probably by the
gastrointestinal tract, is necessary for activity [30].
There is a strong interest from scientists in disease
endemic countries to work on their traditional medi-
cines. With the emergence of organizations such as
ANDi, there is the possibility of investments in the
infrastructure and methodology to enable best practice
for these observational studies to be shared across dis-
ease endemic countries, as well as the analytical and
data interpretation platforms, which cannot be provided
by every disease endemic country.
Potency guided identification of active
ingredients
Once a significant clinical response has been verified,
the active entities must be chemically identified and
characterized. Of course, the natural product extract
could be used directly as a decoction, and in many
countries such extracts are sold commercially. However,
the history of malaria chemotherapy with quinine, lapi-
none and artemisinin shows that more potent and long
N
O
OH
N
H
Quinine    Lapichol    Lapinone 
Atovaquone    Artemisinin   Yingzhaosu  A 
N+
N
H
Cl
Cryptolepine    Curcumin 
Strictosamide 
Protopine   Allocryptopine     Berberine 
Vernodalin    Gedunin 
Figure 2 Structures of molecules from Herbal Medicinal Products
with confirmed or presumed activities in human.
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Natural
product
Source Mechanism of action Highest level demonstration of activity
Quinine Cinchona
genus
Assumed to be similar to chloroquine – and prevent
heme polymerisation.
Early reports of activity with Cinchona bark showed partial
activity with 60g bark over up to 21 days. This represents a
total dose of 350 -700 mg, compared to a current clinical
dose of 500 mg (10 mg/kg salt) given three times a day
for seven days currently - suggesting the bark treatment
was unlikely to be completely effective [31]
Lapachol
Lapinone
Atovaquone
Bignoniaceae Electron transport inhibition Lapachol is a naphthoquinone used to treat malaria and
fevers [41] reported in the 19
th century; it showed weak
activity against P. zophurae infected ducks, when tested in
1943. Lapinone (a close derivative) was confirmed active in
patients with P vivax[42]by intravenous administration for
four days (N=9). Chemical optimisation of the scaffold led
to atovaquone
Artemisinin Artemisia
annua
Free radical activation in the presence of free ferrous
iron – liberated in erythrocytes by parasite digestion of
haemaglobin
Traditional Chinese Medicine. Tea made from 5 g/l leaves
gave 12 mg artemisinin, and clears parasite in 3-4 days
[43]. (Partial protection, since this is much lower than the
WHO recommended dose). More recent studies [44]
achieved doses of 95 mg, with 70% cure on day 7, but still
with high recrudesence and only 30% cure at day 28 [45].
Chemical optimization has led to longer acting synthetic
endoperoxides, currently in development.
Yingzhaosu A Artabotrys
uncinatus
(Ying Zhao)
Presumed to be free radical activation in the presence
of free ferrous iron – liberated in erythrocytes by
parasite digestion of haemoglobin.
Traditional Chinese medicine. The active ingredient was
modified to make Ro-41-3823 which was: Single tested in
patients (N=30) aged 12 -42 years, with parasitaemia >
5000/ml and temperature 37.7 -39.8
oC. 80% patients were
parasite free at day 7 with a single dose of 25 mg/kg.[46]
Discontinued because of lack of superiority over
mefloquine or artemisinin, and because of safety concerns.
Cryptolepine Cryptolepis
sanguinolenta
DNA intercalation [47] Patients between 16 and 60, (N=12) with parasitaemia
between 1000 and 10000/ul given 25 mg/kg extract tid for
seven days. No recrudescence at day 28. Cryptolepine
administered orally to P. berghei-infected mice in doses of
50mg/kg/day for four days reduced parasitaemia by 80%
but the mice were not cured of malaria (Wright et al.,
1996) [48]. Decoction has been standardized by the Faculty
of Pharmacy, Kwame Nkrumah University of Science and
Technology, Ghana and is marketed as PHYTO-LARIA
®.
Curcumin Curcuma
longa
Antioxidant activity? 45 patients have been treated with a nanomilled
curcumin, both vivax and falciparum malaria. Nanomilling
is used to improves bioavailability. No clinical data on
parasitaemia or fever available S Kumesh Kar pers. comm
Strictosamide Nauclea
pobeguinii
Traditional treatment from DR Congo, Herbal medicinal
Product PR 259 CT1 – completed a phase I trial – 1000 mg
t.i.d for 7 days [49] Phase IIb (N=65 patients) treated with
1000 mg tid for three days, followed by 500 mg tid per
day for four days. Parasitaemia fulfilled the WHO research
criteria for malaria. ACPR at day 14 was 90.3% compared
with ASAQ at 96.9%.[50]. Shown to be orally active in
murine models but not in vitro suggesting that
deglycosylation may be required for activity.
Protopine
Allocryptopine
Berberine
Argemone
mexicana
Initial study (N=80) with 80% patients < 5 years old.
Showed need for high dose regimen [51]. Follow up study
(N=199) vs amodiaquine artesunate (N=102) [52] median
age 5 years given for 7-14 days twice per day 89%
successful at day 28, compared with a 95% success rate for
ASAQ. P atients had low parasitaemia (<1000/μL), with
only 17.8% of patients fulfilled the WHO research criteria
for clinical malaria.
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ent is identified and used as the basis of a medicinal
chemistry program. Purification also allows the separa-
tion of the active ingredient from non-active, but toxic
molecules. It should not be forgotten that after self-
administering cinchona bark extract, in the nineteenth
century Christian Hahnemann invented the concept of
homeopathy (infinitely dilute solutions of toxins being
proposed as a cure). The cinchona extract that was sup-
posed to treat malaria gave him malaria-like symptoms
of palpitations, drowsiness, vomiting and feeling cold
(caused by quinidine and other alkaloids), leading him
to coin the concept similia similibus curentur ‘like cures
like’ [31].
Activity based purification requires an assay, and it is
important have an assay which is robust, medium
throughput, and reflects the clinical situation. If the pur-
ification starts with extracts known to be clinically active
in man, the process is much easier. Before moving to in
vitro assays it is important to confirm the clinically
observed activities in vivo (Figure 1), to understand bet-
ter metabolic issues. The standard in vivo models of
infection include the infection of mice with P. berghei
[32]a n dP. yoelii. Of course, if the mouse model does
not confirm the human clinical and anti-parasitic activ-
ity, then the issue is with the murine models, and could
be due to three factors. First, the parasite species is dif-
ferent; and the compound is less potent against the
murine parasite than against P. falciparum. This
difference in potency has been seen in the analysis of
pharmaceutical ‘hits’, and can be discriminated using
humanized or SCID mouse models, which can be
infected with P. falciparum [33]. This model is techni-
cally more challenging, and currently four times as
expensive, but could be usefully deployed where the
human clinical data around an extract are reasonably
solid. Second, as outlined above, host metabolism may
differ in terms of the extent and nature of any metabo-
lism; murine models with human hepatocytes are under
development [34], and this may be of help in the future.
For the moment, the best data would be obtained by
comparing LC-MS/MS data and bioactivity between
human and murine plasma samples, and also by exam-
ining the impact of liver microsomes on the molecules
in the decoctions. Third, the pharmacokinetics may be
different in the two systems; most molecules have a
much shorter half-life in mouse than in human, and this
may require even more frequent administration than
was used clinically, and usually means higher doses.
Once activity is confirmed in murine models, then
either the complete extract can be tested on cellular
models or the extract can be fractionated for testing in
cell-based assays in vitro. Caution is needed here. If it is
known that the patient plasma samples have ex vivo
anti-parasitic activity, and if the final active ingredient
does not have activity at a concentration which is
achieved in plasma during the clinical study, then it is
unlikely to be the real active, unless pharmacological
Table 1 Natural Products and extracts with confirmed or presumed activities in human (Continued)
Vernodalin Vernonia
amygdalina
Known as omubirizi in southwestern Uganda and used for
pain relief and malaria attack, obtained from The Medical
Traditional Healer Association in Rukararwe, Bushenyi
District, Uganda [53] Clinical study for decoction (N=33)
infusion given four times per day for 7 days [54] 67%
response, inclusion criteria allowed patients with <2000/uL
and temperature <37.5
oC. All patients over 12 years old
Febrifugine Dichroa
febrifuga
Ch’ang shan, is a traditional Chinese anti-malarial herb.
Reports from 1942 suggest a dose of 60 mg was clinically
effective [55]. Adverse reaction prevented widespread use
of febrifugine. Halofuginone, a halogenated derivative is
used against coccidiosis, and other derivatives have been
tested against Plasmodium [56]
Gedunin Azadirachta
indica
HSP90 inhibitor [57] Neem extracts are known to be active based on traditional
and observations from India in the early 20
th century [58].
No published recent clinical studies on malaria, although
the aqueous/acetone extract is safe [59] and is registered
in Nigeria in 250mg capsules as IRACARP
®, adult treatment
costs of around $6.00. Most potent ingredient is gedunin
[60]. Murine activity is variable and requires cytochrome
3A4 inhibitor.[61]
There are two well documented commercial uses of herbal medicinal products. The first by the Department of Medicaments traditionnels améliorés, (DMT) in
Mali which uses a mixture of three herbs Cassia occidentalis (leaves), Lippia chevalieri Moldenke (leaves), and Spilanthes oleracea, Jacq (flowers). Sidibe OM, (2006)
Pharmacy Thesis, University of Bamako, Mali http://www.keneya.net/fmpos/theses/2006/pharma/pdf/06P18.pdf.
Ayush-64 is a combination of four Ayurvedic drugs used in India registered by the Central Council for Research in Ayurveda and Siddha (CCRAS). It is formulated
into tablets, and dosed at 1g per day over 5-7 days, at a treatment cost of 14 rupees ($0.28) [62]. Effectiveness, measured as ACPR at day 28 was only 48.9%
compared with 100% for chloroquine, and it is not recommended for use in treatment. However, the activity in man suggests that there is a need for
identification and optimisation of the active ingredients or their metabolites. This figure builds from Table 3 from Willcox and Bodeker 2004 [63].
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molecules have been purified and shown to be active in
the only in the10 – 100 uM range fall into this category.
Significant resources are being used to identify mole-
cules which are unlikely to be useful. By resetting the
thresholds to focus on more potent molecules, and
insisting on observational clinical data and ex vivo analy-
sis, the entire process could be streamlined, and this pit-
fall largely avoided.
Once the active ingredient is identified, then it will
still need some optimization. Moving from quinine via
methylene blue to chloroquine gave significant improve-
ment in frequency of administration; moving from arte-
misinin to artesunate allowed a decrease in dose, and
more consistent bioavailability. This optimization work
will most probably be needed with all new herbal based
actives anti-malarials: the perception that ‘Nature’ has
designed the magic bullet, which just needs to be identi-
fied, produced and marketed, is far from the historical
experience.
It is often suggested that in herbal medicinal products,
more than one active ingredient may be required for
pharmacological activity. This is often given as a reason
for the lack of progress in the identification of new nat-
ural product templates for anti-malarial agents.
Although this is attractive to many in the herbal medic-
i n a lp r o d u c t sw o r l d ,t h ed a t at os u p p o r ts y n e r g yo f
more than one sub-therapeutic ingredient is extremely
sparse in the literature. The three cinchona bark alka-
loids quinine quinidine and cinchonine were shown to
have mild synergy against some, but not all strains
tested in vitro[35]. However, this synergy is not signifi-
cant clinically [36]. The synergy when seen was not suf-
ficiently large that activity was lost on fractionation (a
typical argument why the reductionist approach does
not work. In reality, if biological activity is lost on frac-
tionation it results from inactivation of the active mole-
cule (oxidation, chemical break down). Demonstration
that two active ingredients are absolutely required for
activity means that two of the inactive fractions have to
be recombined to give the activity. In addition, it is
important to differentiate synergy from the presence of
solubilizing or stabilizing factors. Artemisinin is a good
case in point; its potency and solubility can be improved
by the chemical modification to artesunate. In the plant,
the solubility limitation is overcome by solubility poten-
tiation by the flavone casticin [37], or protection by
anti-oxidants [38]. This is more a case of formulation
development than pharmacological synergy. Strictly
speaking synergy requires two active ingredients, that
when combined have a resultant activity greater than
the sum of the two ingredients on their own – casticin’s
anti-malarial activity is only 24 mM. Clinical synergy
could also take place as at the level of exposure levels,
one natural product inhibiting the metabolism of
another in the mixture.
It has been often suggested that crude extracts of qin-
ghaosu are natural a ‘artemisinin combination therapy’,
(playing on the perceptions amongst patients that ACT
is an excellent medicine, but somehow ‘natural’ medi-
cines are better), but this remains to be demonstrated.
The goal of combination therapy from the viewpoint of
the WHO is that one drug should protect the other
against resistance. Both ingredients, therefore, need to
have intrinsic anti-parasitic activities and different
modes of action and mechanisms of resistance. Unless a
natural product extract has two or more such compo-
nents, it is acting as a monotherapy. A strategy to disse-
minate such monotherapy decoctions raises the concern
that it may facilitate the generation of resistance, com-
bining under-dosing with monotherapy [39], however
this danger needs to be balanced with the observation
that the Chinese used this decoction for centuries with-
out generating resistance.
Of the thousands of herbal medicinal products which
have been suggested to be active for malaria, only a very
few have been clearly demonstrated to be active in
patients and animal models prior to fractionation. These
are summarized in Table 1. One reason for this dearth
is simply a lack of funding; but it is a lack of focus.
Modern synthetic organic chemistry grew from natural
products; most organic chemistry projects in the twenti-
eth century involved identifying and structurally charac-
terizing a natural product, and then confirming this
structure by synthesis. Confirmation of biological activ-
ity often comes as an afterthought, rather than a prere-
quisite. The available of mass spectrometry technologies
allowing more rapid characterization of natural products
has further dissociated structure from function. There is
often a disconnection between natural products chemis-
try and clinical and pharmacological reality in practice,
a gap which needs to be addressed.
Marine, fungal and bacterial natural products
Going back to the ethnopharmacological roots is not an
option for two categories of natural products: those
from marine organisms, and those from fungal fermen-
tations. Work on marine organisms is still in its infancy
compared to plant natural products, with the first medi-
cine being launched over the last seven years (cancer
and chronic pain) [40]. Microbial fermentation products
continue to be of interest, several groups have worked
on trying to identify a macrolide with better anti-malar-
ial activity than azithromycin. Screening the diversity
collections of Japanese pharmaceutical companies may
throw more light on this question, since they have been
slower to abandon microbial natural products than their
US or European counterparts. However, it is still
Wells Malaria Journal 2011, 10(Suppl 1):S3
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lar potency and truly novel chemistry.
Networks for success
Partnerships such as Medicines for Malaria Venture
(MMV) and Drugs for Neglected Diseases Initiative
(DNDi) have proved their ability to develop and deliver
new anti-malarial medicines: products from their part-
nerships treated over fifty million children in the last 12
months. However, the leadership in the identification
and characterization of herbal medicinal products
requires local knowledge and sensitivity. It implies deep
involvement of the Health Ministries and Drug Registra-
tion Authorities of the disease endemic countries, since
many countries already approve the sale of such pro-
ducts. Sovereignty issues around natural products also
argue strongly that these initial endeavours are best sup-
ported locally, in countries investing in their own patri-
mony of ethnopharmacology, perhaps supported with
technology co-ordination and financial support from
organisations such as the African Network for Drugs
and Diagnostics Innovation (ANDi). Some malaria ende-
mic countries will consider funding such ethnopharma-
cology-based programmes as a way of fulfilling their
Abuja commitments to malaria research and develop-
ment. For now, the key gap is to fund collaborations
with a bigger picture; combining natural products and
observational clinical studies from the start. Longer
term it means bringing together the networks of plant
scientists, clinicians, pharmacologists and analytical che-
mists to form productive collaborations, and deliver new
medicines.
Conclusions
All of the medicines that are used today against malaria
come from natural product lineages which can be traced
back to herbal medicinal products: quinine, lapachol and
artemisinin. From each of these starting points, new
innovative molecules have been developed by medicinal
chemistry, formulation development and combination
therapy that are better suited to the needs of the patients.
The trend over the last few decades has moved towards a
reductionist ‘smash and grab’ approach to natural pro-
ducts, which has not delivered the same success. This
recent success of cell based screening over target screen-
ing for pharmaceutical libraries is forcing us to re-evalu-
ate our approach to drug discovery. Herbal medicinal
products carry one strategic advantage – that in several
cases we know that there is an activity in patients. Once
the clinical activity of a herbal medicinal product is veri-
fied in observational studies, the anti-parasitic activity of
the plasma samples on parasites could be confirmed ex
vivo, and characterization of the decoction and the
plasma samples using mass spectrometry and HLPC
separations. Once the active ingredients are identified it
is likely that medicinal chemistry will be needed to opti-
mize it for clinical use. Disease endemic countries play a
key role in this process. Countries with registered Herbal
Medicinal Products have a responsibility to their patients
to understand the mode of action better. Organisations
such as the African Network for Drugs and Diagnostics
Innovation (ANDi) can play a key role in helping to stan-
dardize the clinical protocols used to understand herbal
medicinal products, as well as providing the technology
network to assist the activity guided purification of the
active ingredients. Natural products have been the start-
ing points for new malaria medicines over the last cen-
tury. By making the most of the potential for clinical
data, it is possible that they could continue to influence
our thinking for the next century.
List of abbreviations used
Artemisinin combination therapy (ACT); African Network for Drugs and
Diagnostics Innovation (ANDi)
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